Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 

7 Binary Options

 

Enter Stock Symbol:  

Caladrius Bio (CLBS)

4.22 -0.03 (-0.71%)

8/23/2017  3:59pm

Open:

4.20

Pre. Close:

4.25

High:

4.30

Low:

4.12

Volume:

18,003

Market Cap:

N/A

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

4.36 - 4.45

4.45 - 4.59

Low:

3.91 - 3.98

3.98 - 4.08

Close:

4.08 - 4.21

4.21 - 4.41

Technical analysis  (as of: 2017-08-23 4:41:58 PM)

Overall:

      

Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 5.08     One year: 5.93

Support:

Support1: 4.01    Support2: 3.80

Resistance:

Resistance1: 4.35    Resistance2: 5.08

Pivot:

4.12

Moving Averages:

MA(5): 4.27     MA(20): 4.11

MA(100): 4.50     MA(250): 4.39

MACD:

MACD(12,26): 0.02     Signal(12,26,9): -0.02

%K %D:

%K(14,3): 81.82     %D(3): 85.25

RSI:

RSI(14): 52.06

52-Week:

High: 7.79  Low: 2.65  Change(%): -14.7

Average Vol(K):

3-Month: 2646  10-Days 1338

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
CLBS has closed below upper band by 35.6%. Bollinger Bands are 1.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 10 Mar 2017 03:00:00 GMT
Is Caladrius Biosciences Inc. A Buy?

Mon, 17 Apr 2017 13:18:45 GMT
The Strange Case Of Caladrius Biosciences

Thu, 16 Mar 2017 23:26:15 GMT
Hitachi Chemical Signs Agreement to Purchase from Caladrius Biosciences the ...

Fri, 05 Feb 2016 12:13:48 GMT
Caladrius Biosciences Needs A Major Strategic Change

Wed, 19 Jul 2017 12:00:00 GMT
Caladrius Biosciences Announces that 50% of Subjects Have Been Treated in the ...

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology Medical Research

Shares Out. (M)

Shares Float (M)

% Held by Insiders

% Held by Institutions

Shares Short (K)

Shares Short Prior Month (K)

Stock Financials

EPS

EPS Est. Current Year

-2.420

EPS Est. Next Year

-3.050

EPS Est. Next Quarter

-0.790

Forward EPS

1.#IO

Book Value (p.s.)

PEG Ratio

Profit Margin

Operating Margin

Return on Assets (ttm)

Return on Equity (ttm)

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

Qtrly Earnings Growth

Operating Cash Flow (M)

Levered Free Cash Flow (M)

FoxReading.com

Valuation

P/E

P/E Growth Ratio

P/BV

P/S

P/CF

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.